CHC Healthcare Group recently announced March revenue of NT$560 million, marking a substantial 151% increase compared to the same period last year. First-quarter revenue has exceeded NT$1 billion, defying seasonal trends and setting a new first-quarter record since the company’s listing. While many medical device stocks have been affected by tariff issues recently, CHC Healthcare clarified that over 95% of its product sales are within the Taiwan market, with only a small portion shipped to China and Indonesia. As the company does not export products to the U.S., the Trump-era tariff policies have no impact on its operations.

CHC Healthcare stated that, in addition to the recognition of high-value equipment orders in March—which led to the highest single-month revenue in the past 18 months—this year’s strong market demand has driven robust order volume in the medical equipment segment. Meanwhile, its chain pharmacy business continues to expand rapidly. The company anticipates that, on top of the strong performance in the first quarter, the second half of the year will usher in peak season for high-end equipment acceptance, further boosting its operational momentum. Analysts expect CHC Healthcare’s annual revenue this year to significantly surpass previous records, with profit performance also highly anticipated.

In addition, CHC Healthcare has seen notable success in promoting proton therapy in recent years. In early March, it signed a proton therapy system sales contract with the Ministry of National Defense’s medical center. Another contract with Changhua Christian Hospital is also in hand. Together, these two major deals total nearly NT$3 billion, representing a strong driver of future growth and reinforcing a positive outlook for the company’s overall development.

Resource: 承業醫3月營收5.6億元倍增 首季寫同期新猷